glp 1 for people without diabetes GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Optimizing GLP-1 therapies for obesity
Description
reviewed oncological FDG PET-CT scans of patients actively taking GLP-1 receptor agonists
This is the most straightforward pathway to reduced effectiveness
GLP-1 GLP-1GLP-1GLP-1 Q2
Insurance providers can differ in their coverage of weight loss drugs
